Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature Review
Conclusions include the following: MG in HIV-infected patients should be managed similarly to individuals without HIV infection; half develop moderate–severe MG; MG symptoms may worsen within 6 months of antiretroviral initiation; safety monitoring must include plasma HIV viral load estimation. Isoniazid prophylaxis may not be indicated in all cases.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: African Health | Brain | Databases & Libraries | Gammagard Liquid | Herpes | Methotrexate | Myasthenia Gravis | Neurology | Privigen | South Africa Health | Tuberculosis